




Supplementary Figures




Supplementary Figure 1. A comparison of the kinetics of GRK2 and Arr3 recruitment to the plasma membrane in response to D2R activation according to bystander hiBRET, related to Figure 1. (A) A bystander hiBRET-based D2R-mediated Arr3 recruitment assay wherein Arr3 is fused to Sp1-Nanoluciferase donor (Sp1-donor-Arr3). Upon receptor activation, Sp1-donor-Arr3 is recruited to the plasma membrane where a membrane-anchored SH3-citrine acceptor is localized, resulting in an increase in BRET. **(B)** Representative traces of D2R-mediated GRK2 recruitment and Arr3 recruitment. **(D)** Summary of the on-kinetics of GRK2 recruitment and Arr3 recruitment. unpaired t-test, ** $p = 0.0016$.




Supplementary Figure 2. Direct BRET between GRK2 and D2R or Gβγ, related to Figure 2. (A) Dopamine-induced D2R activation enhances BRET between GRK2-donor-Sp1 and mVenus acceptor-tagged D2R (D2R-acceptor). (B) PTX reduces but does not abolish dopamine-induced BRET between D2R and GRK2. paired t-test, * $p < 0.05$. (C) Dopamine-induced D2R activation enhances BRET between GRK2-donor-Sp1 and split mVenus acceptor-tagged Gβ₁γ₂. (D) PTX reduces but does not abolish dopamine-induced BRET between D2R and Gβ₁γ₂. paired t-test, * $p < 0.05$. (E) Recruitment of GRK2-donor-Sp1 to split acceptor-tagged Gβ₁γ₂ in the presence of increasing amount of PTX cDNA. $n = 3$ independent experiments each performed in triplicate. (F) Dopamine-induced D2R activation promotes the interaction between D2R-acceptor and GRK2(R587Q)-donor-Sp1 but not GRK2(Δ2-15)-donor-Sp1. paired t-test, * $p < 0.05$. (G) Dopamine-induced D2R activation promotes the interaction between split acceptor-tagged Gβ₁γ₂ and GRK2(Δ2-15)-donor-Sp1 but not GRK2(R587Q)-donor-Sp1. paired t-test, * $p < 0.05$.




Supplementary Figure 3. Dynamics of G β γ -dependent and -independent GRK3 recruitment, related to Figure 2. (A) Representative traces of the recruitment of GRK3-WT, GRK3($\Delta 2-15$), or GRK3(R587Q) to the plasma membrane in response to 10 μ M dopamine-induced D2R activation. (C) Maximal recruitment of GRK3-WT or GRK3 mutants to the plasma membrane. one-way ANOVA, $F = 20.1$, $*p < 0.05$, $**p < 0.01$. (D) Summary of the on-kinetics of GRK3-WT, GRK3($\Delta 2-15$), or GRK3(R587Q) to the plasma membrane in response to 10 μ M dopamine. RM one-way ANOVA, $F = 4.8$, $*p < 0.05$. (E) Reduction in maximal GRK3 recruitment to the plasma membrane after 60 minutes. RM one-way ANOVA, $F = 9.9$, $**p < 0.05$.




Supplementary Figure 4. GRK2 recruitment in the presence of G_{i1} or G_{oA} , related to Figure 3. (A) Summary of the effect of PTX resistant- G_{i1} or - G_{oA} overexpression on GRK2-WT recruitment compared to PTX alone (-) in response to 10 μ M dopamine. RM one-way ANOVA, $F = 24.0$, Tukey post-hoc test, $*p < 0.05$, $***p < 0.001$. **(B)** A BRET-based assay wherein D2R activation promotes the dissociation of a heterotrimeric G protein and the release of mVenus split acceptor-tagged $G\beta_1\gamma_2$, which then binds a Renilla luciferase donor tagged-C-terminal fragment of GRK3 (GRKct-donor). **(C)** Dopamine-induced D2R activation promotes greater $G\beta_1\gamma_2$ release from G_{oA} than G_{i1} . paired t-test, $*p < 0.05$. **(D)** Summary of the reduction in the potency of dopamine for GRK2($\Delta 2-15$) or GRK2(R587Q) recruitment in the presence of PTX and either PTX-resistant $G_{\alpha i1}$ or $G_{\alpha oA}$.




Supplementary Figure 5. Extended analysis of the effects of G $\beta\gamma$ -dependent and -independent GRK2 recruitment on arrestin, related to Figure 4. (A) Difference between the potency of dopamine of GRK2(Δ 2-15) or GRK2(R587Q) and that for Arr3 in the presence of GRK2-WT. (B) 100 nM dopamine (dotted line) fully activates GRK2(Δ 2-15) but has no effect on GRK2(R587Q) in cells co-expressing G $_{\text{oA}}$. (C) Representative trace of Arr3 recruitment in the presence of G $_{\text{oA}}$ and GRK2-WT in response to 100 nM or 100 μ M dopamine. (D) Summary of D2R-mediated Arr3 recruitment in the presence of G $_{\text{oA}}$ and GRK2-WT in response to varying concentrations of dopamine. paired t-test, ***p < 0.001. (E) Schematic of a novel hiBRET-based D2R internalization assay. D2R was tagged with a donor and helper peptide Sp1, followed by co-expression with mem-acceptor-SH3 in Δ Q:Arr2/3 cells, resulting in BRET at the plasma membrane. Upon activation, the receptor undergoes GRK and arrestin dependent-internalization, reducing the BRET signal. (F) Summary of D2R-dependent internalization in Δ Q:Arr2/3 cells transfected with GRK2-WT, GRK2(Δ 2-15), or GRK2(R587Q). Arr3 was co-expressed in all conditions. 100 μ M dopamine was applied to all conditions, with an additional condition in which 316 nM dopamine was applied to GRK2-WT. RM one-way ANOVA, F = 13.1, **p < 0.01, ***p < 0.001, ****p < 0.0001. (G) Dose-response curves showing the similarity in the effect of (i) 316 nM dopamine on GRK2-WT-dependent Arr3 recruitment and (ii) 100 μ M dopamine on GRK2(R587Q)-dependent Arr3 recruitment.




Supplementary Figure 6. Extended analysis of the effects of $G\beta\gamma$ -dependent and -independent GRK2 recruitment on G protein, related to Figure 4. (A) Summary of maximal D2R-dependent G protein activation in $\Delta Q:Arr2/3$ cells transfected with GRK2-WT, GRK2($\Delta 2-15$), or GRK2(R587Q). 100 μM dopamine was applied to all conditions. one-way ANOVA, $F = 24.0$, $*p < 0.05$, $**p < 0.01$. (B) Schematic of an electrophysiology-based D2R-mediated GIRK activation assay. (C) Summary of maximal D2R-mediated GIRK current in $\Delta Q:Arr2/3$ cells transfected with GRK2-WT, GRK2($\Delta 2-15$), or GRK2(R587Q). Arr3 was co-expressed in all conditions. 10 μM dopamine was applied to all conditions. one-way ANOVA, $F = 25.3$, $****p < 0.0001$. (D) On-kinetics of dopamine-induced GIRK activation. unpaired t-test, $*p < 0.05$. (E) Desensitization of dopamine-induced GIRK current. one-way ANOVA, $F = 51.9$, $****p < 0.0001$. (F) Schematic of BRET-based D2R-mediated cyclic AMP (cAMP) inhibition assay using the cAMP sensor Nluc-EPAC-VV. (G) Summary of GRK2-dependent disinhibition of the inhibitory effect of D2R on cAMP. RM one-way ANOVA, $F = 25.5$, $***p < 0.001$. (H) Summary of GRK2-dependent disinhibition of the inhibitory effect of D2R on cAMP over time.



Supplementary Figure 7. Extended analysis of the effects of G $\beta\gamma$ -dependent and -independent GRK2 recruitment on ERK signaling, related to Figure 4. (A) Schematic of D2R-mediated enhancement of ERK activity using an established BRET-based biosensor. (B) Summary of D2R-dependent effects on ERK activity in ΔQ :Arr2/3 cells transfected with GRK2-WT, GRK2(Δ 2-15), or GRK2(R587Q) compared to control. Arr3 was co-expressed in all conditions. 100 μ M dopamine was applied to all conditions. RM one-way ANOVA, F = 18.4, **p < 0.01, *p < 0.05.




Supplementary Figure 8. Extended analysis of D2R ligand-induced effects on Gβγ-dependent and -independent GRK2 recruitment, related to Figure 5. (A) D2R ligands tested in this study. A saturating concentration of each compound (10 μM) was compared to dopamine (100 μM). **(B)** Summary of GRK2-WT, GRK2(Δ2-15), and GRK2(R587Q) recruitment in response to a panel of D2R ligands. Responses normalized to dopamine at GRK2-WT. **(C)** Preference of D2R ligands for GRK2(Δ2-15) over GRK2(R587Q). **(D)** Representative traces of Gβ₁γ₂ release in response to a panel of D2R ligands. **(E)** Summary of Gβ₁γ₂ release in response to a panel of D2R ligands. **(F)** Relationship between GRK2(Δ2-15) recruitment and Gβ₁γ₂ release in response to a panel of D2R ligands. Linear regression, Slope = 1.16, R² = 0.86.



Supplementary Figure 9. Extended analysis of the effect of G $\beta\gamma$ -dependent and -independent GRK2 recruitment on biased signaling, related to Figure 5. (A) D2R ligands tested in this study. (B) Schematic of a bystander BRET-based G protein recruitment assay. The G α subunit was engineered to operate independently of G $\beta\gamma$, localize to the cytosol rather than the membrane, and is fused to an Nluc donor (Nluc–miniG_{si}). Receptor activation results in the recruitment of Nluc–miniG_{si} to D2R, resulting in bystander BRET with a membrane-anchored acceptor (mem-acceptor). (C) Representative traces of G α recruitment in response to a panel of D2R ligands. A saturating concentration of each compound (10 μ M) was compared to dopamine (100 μ M). (D) Summary of G α recruitment in response to a panel of D2R ligands. (E) Representative traces of Arr3 recruitment in Δ Q:Arr2/3 cells overexpressing GRK2-WT (left) or

GRK2(R587Q) (*right*) recruitment in response to a panel of D2R ligands. A saturating concentration of each compound (10 μM) was compared to dopamine (100 μM). **(F)** Summary of GRK2-WT- or GRK2(R587Q)-dependent Arr3 recruitment in response to a panel of D2R ligands. **(G)** Bias plots for a panel of D2R ligands.



Supplementary Figure 10. Extended analysis of Gβγ-dependent and -independent GRK2 recruitment to diverse GPCRs, related to Figure 6. (A) Summary of GRK2-WT, GRK2(Δ2-15), and GRK2(R587Q) recruitment to a panel of GPCRs. The following agonists were applied at saturating concentrations: dopamine receptors D1R-D5R = 100 μM dopamine; muscarinic acetylcholine receptors

M1R-M5R = 10 μ M acetylcholine; metabotropic glutamate receptors mGluR1-7 = 1 mM glutamate; GABA receptor GABA_BR = 10 μ M GABA; glucagon receptor GCGR = 100 μ M glucagon; glucagon-like receptor GLP1R = 1 μ M GLP-1; beta adrenergic receptor β 2AR = 10 μ M isoproterenol; serotonin receptors 5HT_{2A-C} = 10 μ M serotonin; angiotensin receptor AT₁R = 10 μ M angiotensin II; kappa opioid receptor κ OR = 10 μ M dynorphin A; mu opioid receptor μ OR = 10 μ M DAMGO. **(B)** Representative traces for GPCRs categorized based on their GRK2 recruitment profiles. This includes receptors that: (1) do not recruit GRK2 (*non-recruiting*), (2) recruit similar levels of GRK2(Δ 2-15) and GRK2(R587Q) (*balanced*), (3) recruit more GRK2(Δ 2-15) than GRK2(R587Q) (*G β γ -preferring*), (4) recruit GRK2(R587Q) but not GRK2(Δ 2-15) (*G β γ -independent*), (5) recruit GRK2(Δ 2-15) but decrease in their basal association with GRK2(R587Q) (*G β γ -dependent, \downarrow G β γ -independent*), and (6) recruit GRK2(Δ 2-15) but have no effect on GRK2(R587Q) (*G β γ -dependent, \leftrightarrow G β γ -independent*). Receptors were classified as being capable of promoting G β γ -dependent or -independent GRK2 recruitment if the magnitude of their effects on these mechanisms was >5% of GRK2-WT recruitment to D2R. **(C)** Summary of the basal association between GPCRs and GRK2(R587Q) ranked from lowest to highest. **(D)** Summary of the effect of glutamate (1 mM) or FITM (10 μ M) on the basal association between mGluR1 and GRK2(R587Q). paired t-test, *p < 0.05.

		G protein		Arrestin		ERK
		Activation	Signaling	Recruitment	Internalization	
Balanced agonist		●	●	●	●	●
G protein biased agonist	↔ <i>Gβγ-independent</i>	●	●	●	●	●
	↓ <i>Gβγ-independent</i>	●	●	●	●	●
Arrestin biased agonist	↑ <i>Gβγ-dependent</i>	●	●	●	●	●
	↑ <i>Gβγ-independent</i>	●	●	●	●	●
	↑ <i>Gβγ-dependent and independent</i>	●	●	●	●	●

Supplementary Figure 11. Predicted biased agonist profiles based on this study, related to Discussion. Endogenous ligands are, by definition, balanced agonists that fully engage both G proteins and arrestins. In principle, G protein biased agonists stabilize conformational states that preferentially couple to G proteins. However, Gβγ-dependent GRK2 recruitment counteracts this bias by suppressing G protein signaling and promoting receptor phosphorylation and subsequent arrestin recruitment. To maintain bias, G protein biased agonists should avoid non-canonical Gβγ-independent GRK2 recruitment, either by not activating this pathway or by suppressing basal receptor:GRK2 interactions. Conversely, arrestin biased agonists stabilize receptor states that favor arrestin binding. However, many GPCRs cannot efficiently recruit GRK2 in the absence of G protein activation and Gβγ release, limiting opportunities for arrestin-biased drug discovery. Agonists that preferentially stabilize receptor conformations that favor Gβγ-independent GRK2 recruitment — and thereby arrestin — independently of G protein represents a path towards purely arrestin biased agonists. However, such ligands would support ERK activation while only partially promoting arrestin recruitment and failing to drive arrestin-dependent internalization. Finally, arrestin biased agonists that promote both Gβγ-dependent and -independent would still require some degree of G protein activation but offer greater potential for arrestin recruitment.